These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 2514093

  • 1. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D, Strandberg L, Grundström T, Ny T.
    Eur J Biochem; 1989 Dec 22; 186(3):523-33. PubMed ID: 2514093
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M.
    Eur J Biochem; 1992 Jul 01; 207(1):177-83. PubMed ID: 1321039
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.
    Hekman CM, Loskutoff DJ.
    Arch Biochem Biophys; 1988 Apr 01; 262(1):199-210. PubMed ID: 3128176
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
    Lawrence DA, Strandberg L, Ericson J, Ny T.
    J Biol Chem; 1990 Nov 25; 265(33):20293-301. PubMed ID: 1700786
    [Abstract] [Full Text] [Related]

  • 10. Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1.
    Franke AE, Danley DE, Kaczmarek FS, Hawrylik SJ, Gerard RD, Lee SE, Geoghegan KF.
    Biochim Biophys Acta; 1990 Jan 19; 1037(1):16-23. PubMed ID: 2403813
    [Abstract] [Full Text] [Related]

  • 11. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
    Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D.
    Eur J Biochem; 1988 Aug 15; 175(3):531-40. PubMed ID: 3261688
    [Abstract] [Full Text] [Related]

  • 12. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H.
    Blood; 1991 Sep 01; 78(5):1254-61. PubMed ID: 1715220
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
    Reilly CF, Hutzelmann JE.
    J Biol Chem; 1992 Aug 25; 267(24):17128-35. PubMed ID: 1512250
    [Abstract] [Full Text] [Related]

  • 14. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.
    Lee HJ, Im H.
    Protein Expr Purif; 2003 Sep 25; 31(1):99-107. PubMed ID: 12963346
    [Abstract] [Full Text] [Related]

  • 15. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H.
    J Biol Chem; 1990 Aug 05; 265(22):13029-35. PubMed ID: 1695900
    [Abstract] [Full Text] [Related]

  • 16. High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli.
    Sisk WP, Davis GL, Kingsley D, Chiu AT, Reilly TM.
    Gene; 1990 Dec 15; 96(2):305-9. PubMed ID: 2269442
    [Abstract] [Full Text] [Related]

  • 17. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ, Krikun G, Papp C, Aigner S, Schatz F.
    J Clin Endocrinol Metab; 1995 Apr 15; 80(4):1100-5. PubMed ID: 7714076
    [Abstract] [Full Text] [Related]

  • 18. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
    de Serrano VS, Castellino FJ.
    J Biol Chem; 1990 Jun 25; 265(18):10473-8. PubMed ID: 2113057
    [Abstract] [Full Text] [Related]

  • 19. Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
    Zeheb R, Rafferty UM, Rodriguez MA, Andreasen P, Gelehrter TD.
    Thromb Haemost; 1987 Dec 18; 58(4):1017-23. PubMed ID: 3127913
    [Abstract] [Full Text] [Related]

  • 20. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA, Olson ST, Palaniappan S, Ginsburg D.
    Biochemistry; 1994 Mar 29; 33(12):3643-8. PubMed ID: 8142362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.